1. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998;39:Suppl 7. S22-S26.
2. Asconape JJ. Some common issues in the use of anti-epileptic drugs. Semin Neurol 2002;22:27-39.
3. Sussman NM, McLain LW Jr. A direct hepatotoxic effect of valproic acid. JAMA 1979;242:1173-1174.
4. Bryant AE 3rd, Dreifuss FE. Valproic acid hepatic fatalities III US experience since 1986. Neurology 1996;46:465-469.
5. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:379-385.
6. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987;28:Suppl 3. S64-S70.
7. Pellock JM. In: Willmore LJ, editor. Felbamate. New antiepileptic drugs: basic and clinical use in children and adults. American Epilepsy Society annual course 1998;12. 06. San Diego: H1-H13.
8. Hawkins CF, Meynell MJ. Macrocytosis and macrocytic anaemia caused by anticonvulsant drugs. Q J Med 1958;27:45-63.
9. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Mayersdorf A, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-151.
10. Browne TR. In: Engel JJ, Pedley TA, editor. Phenytoin and other hydantoins. Epilepsy: comprehensive textbook 1997;Philadelphia: Lippincott-Raven Publishers. 1557-1579.
11. Verrotti A, Greco R, Matera V, Altobelli E, Morgese G, Chiarelli F. Platelet count and function in children receiving sodium valproate. Pediatr Neurol 1999;21:611-614.
12. Gidal B, Spencer N, Maly M, Pitterle M, Williams E, Jones J, et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 1994;44:1418-1422.
13. Gilhus NE, Matre R. Carbamazepine effects on mononuclear blood cells in epileptic patients. Acta Neurol Scand 1986;74:181-185.
14. Livingston S, Villamater C, Sakata Y, Pauli LL. Use of carbamazepine in epilepsy. Results in 87 patients. JAMA 1967;200:204-208.
15. Hart RG, Easton JD. Carbamazepine and hematological monitoring. Ann Neurol 1982;11:309-312.
16. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997;38:1265-1269.
17. Kälviäinen R, Nousiainen I, Mantijarvi M. Initial vigabatrin monotherapy is associated with increased risk of visual field constriction: a comparative follow-up study with patients on initial carbamazepine monotherapy and healthy control. Epilepsia 1989;39:72.
18. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37:Suppl 2. S18-S22.
19. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388.
20. Roos KL, Flippern CC II, Hingtgen C, Markand ON, Hattson DH, Wojcieszek J, et al. Neurologic disorders and pregnancy. Continnum: Lifelong learning in neurology 2000;8-63.